Black Diamond Therapeutics reported Q2 results with robust silevertinib responses, no new brain mets, and cash expected to last into the second half of 2028.
Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.
